Media about us

12 February 2018

A new training center will be established in NovaMedica Innotech

GMP News

NovaMedica, a Russian pharmaceutical company and the investment project of RUSNANO, has announced the collaboration in the area of knowledge and technology transfer between NovaMedica Innotech, an R&D center, and Evonik, a German company and a leader in the global market of excipients for pharmaceutical industry.

02 February 2018

Syndax entered a clinicial trial collaboration with AstraZeneca

GMP News

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.

02 February 2018

AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

Nick Paul Taylor / FierceBiotech

AstraZeneca and Syndax have teamed up to test immune checkpoint inhibitor Imfinzi in combination with CSF1R inhibitor SNDX-6352. Syndax is set to put the cocktail through a phase 1b solid tumor trial to equip both companies to sponsor midphase trials to demonstrate its safety and efficacy.

23 January 2018

Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

#WBSMoscow

As the blockchain revolution gains momentum around the world, Trescon had the opportunity to interview Maxim Gorbachev, a Managing Partner at RMI Partners, on the evolving nature of blockchain. RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies.

22 January 2018

Russia grants Hermes GMP certification at German and Austrian plants

Dan Stanton / In-Pharma Technologist.com

Since 2011, Russian policy has favoured local production in e􀃗orts to reduce reliance on pharmaceutical imports. Vladimir Putin’s ‘Pharma 2020’ policy pushes for as much 90% of drugs consumed in Russia to be made domestically by 2020. Such policies have led multinationals to tap the market through collaborations with domestic drugmakers. Pfizer, for example, teamed with Russian pharma firm NovaMedica last May to build an aseptic manufacturing plant in.

19 January 2018

Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

Catherine Longworth / MedTech Insight

Israeli start up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.

11 January 2018

Genentech, Syndax expand HDAC-PD-L1 combination pact

Nick Paul Taylor / FierceBiotech

Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

28 December 2017

NovaMedica Innotech R&D center meets Russian GMP standards

GMP News

NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the conclusion of the Russian Ministry of Industry and Trade on the compliance of the production site of NovaMedica Innotech R&D center, a subsidiary of NovaMedica, with the Russian Good Manufacturing Practice (GMP) standards.

26 December 2017

Authorities approve the application of NovaMedica for a new production facility

GMP News

NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the approval of the Inter-Agency Commission for conclusion of Special Investment Contract (SPIC) under the investment project aimed at establishing a pharmaceutical plant for sterile injectable drugs in the Kaluga region.

11 December 2017

An Epic quest to detect cancer

Bradley J. Fikes / The San-Diego Union Tribune

Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.